Direct Comparison of 4 Very Early Rule-Out Strategies for Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin I
Overview
Authors
Affiliations
Background: Four strategies for very early rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I (hs-cTnI) have been identified. It remains unclear which strategy is most attractive for clinical application.
Methods: We prospectively enrolled unselected patients presenting to the emergency department with symptoms suggestive of acute myocardial infarction. The final diagnosis was adjudicated by 2 independent cardiologists. Hs-cTnI levels were measured at presentation and after 1 hour in a blinded fashion. We directly compared all 4 hs-cTnI-based rule-out strategies: limit of detection (LOD, hs-cTnI<2 ng/L), single cutoff (hs-cTnI<5 ng/L), 1-hour algorithm (hs-cTnI<5 ng/L and 1-hour change<2 ng/L), and the 0/1-hour algorithm recommended in the European Society of Cardiology guideline combining LOD and 1-hour algorithm.
Results: Among 2828 enrolled patients, acute myocardial infarction was the final diagnosis in 451 (16%) patients. The LOD approach ruled out 453 patients (16%) with a sensitivity of 100% (95% confidence interval [CI], 99.2%-100%), the single cutoff 1516 patients (54%) with a sensitivity of 97.1% (95% CI, 95.1%-98.3%), the 1-hour algorithm 1459 patients (52%) with a sensitivity of 98.4% (95% CI, 96.8%-99.2%), and the 0/1-hour algorithm 1463 patients (52%) with a sensitivity of 98.4% (95% CI, 96.8%-99.2%). Predefined subgroup analysis in early presenters (≤2 hours) revealed significantly lower sensitivity (94.2%, interaction =0.03) of the single cutoff, but not the other strategies. Two-year survival was 100% with LOD and 98.1% with the other strategies (<0.01 for LOD versus each of the other strategies).
Conclusions: All 4 rule-out strategies balance effectiveness and safety equally well. The single cutoff should not be applied in early presenters, whereas the 3 other strategies seem to perform well in this challenging subgroup.
Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00470587.
Gajewski P, Krintus M, Chudas K, Pawlowski R, Laskowska E, Jasiewicz M EJIFCC. 2024; 35(1):10-22.
PMID: 38706733 PMC: 11063784.
A Single High-Sensitivity Cardiac Troponin T Strategy for Ruling Out Myocardial Infarction.
Gilje P, Mohammad M, Roos A, Ekelund U, Bjork J, Lindahl B Emerg Med Int. 2024; 2024:2241528.
PMID: 38567081 PMC: 10985641. DOI: 10.1155/2024/2241528.
The Utility of Urinary Titin to Diagnose and Predict the Prognosis of Acute Myocardial Infarction.
Arase M, Nakanishi N, Tsutsumi R, Kawakami A, Arai Y, Sakaue H Int J Mol Sci. 2024; 25(1).
PMID: 38203744 PMC: 10778763. DOI: 10.3390/ijms25010573.
Hatherley J, Salmon T, Collinson P, Khand A Open Heart. 2023; 10(2).
PMID: 38151261 PMC: 10753736. DOI: 10.1136/openhrt-2023-002366.
Serial troponin-I and long-term outcomes in subjects with suspected acute coronary syndrome.
Pareek M, Kristensen A, Vaduganathan M, Byrne C, Biering-Sorensen T, Lassen M Eur J Prev Cardiol. 2023; 31(5):615-626.
PMID: 38057157 PMC: 11109926. DOI: 10.1093/eurjpc/zwad373.